IDegLira HIGH Trial
NCT03737240 on ClinicalTrials.gov · last registry update 2023-09-08
A small phase 3 — 145 participants, against a typical 424. The sponsor logged completion for 8 July 2022. Primary outcome, as filed: Change in Hemoglobin A1c (HbA1c). liraglutide is approved in the US, but not for diabetes — a registration here is not an approval, and most drugs tested in a new condition never get one for it.
- Status
- COMPLETED
- Phase
- P3
- Drug
- liraglutideSaxenda, Victoza, Xultophy
- Sponsor
- Emory University
- Sponsor type
- Other
- Enrollment
- 145
- Started
- 2019-01-15
- Primary completion
- 2022-07-08 actual
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Change in Hemoglobin A1c (HbA1c)
Conditions studied
Diabetes Mellitus
Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.